Blog
RSS FeedPosted by Michael Wonder on 26 Sep 2022
Novavax appeals to ATAGI to change advice as vaccine uptake falls behind
25 September 2022 - Novavax was hailed as the fix to Australia’s low inoculation rate and “the vaccine for anti-vaxxers”. So ...
Posted by Michael Wonder on 26 Sep 2022
ATAGI recommend the COVID-19 vaccination for some children aged 6 months to under 5 years
26 September 2022 - Australia’s immunisation experts, the Australian Technical Advisory Group on Immunisation, recommend COVID-19 vaccination for some children aged ...
Posted by Michael Wonder on 24 Sep 2022
Moderna asks FDA to authorise omicron Covid boosters for children as young as 6 years old
23 September 2022 - The Centers for Disease Control and Prevention, in a document published Tuesday, said it expects children to ...
Posted by Michael Wonder on 23 Sep 2022
COVID-19 vaccine safety report (23 September 2022)
23 September 2022 - To 18 September 2022, the TGA has received 712 reports which have been assessed as likely to ...
Posted by Michael Wonder on 23 Sep 2022
Pfizer applies to Swissmedic for authorisation of another COVID-19 vaccine
22 September 2022 - Pfizer said on Thursday it had submitted an application to Swissmedic for authorisation of a further ...
Posted by Michael Wonder on 22 Sep 2022
13 million Novavax doses due to expire as Australians stick to mRNA boosters
21 September 2022 - Novavax COVID vaccines procured by the federal government in the hopes of convincing hesitant Australians to ...
Posted by Michael Wonder on 21 Sep 2022
EU health regulator says COVID pandemic not over
20 September 2022 - An official at the European Union's drugs regulator said on Tuesday the COVID-19 pandemic was not ...
Posted by Michael Wonder on 21 Sep 2022
TGA provisionally approves Pfizer's COVID-19 vaccine, Comirnaty (tozinameran), for use as a booster dose in individuals 5 years and older
21 September 2022 - On 20 September 2022, the TGA provisionally approved Pfizer's COVID-19 vaccine, Comirnaty (tozinameran) for use as ...
Posted by Michael Wonder on 19 Sep 2022
Pharmacists can now prescribe Paxlovid, but barriers persist
19 September 2022 - Recently, the FDA expanded access to COVID-19 treatment by authorising state-licensed pharmacists to prescribe Paxlovid to eligible ...
Posted by Michael Wonder on 17 Sep 2022
EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines
16 September 2022 - The EMA’s CHMP has recommended converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer’s ...
Posted by Michael Wonder on 17 Sep 2022
Take whatever COVID booster you can get, says head of EU drugs watchdog
14 September 2022 - People in Europe should take whatever COVID-19 booster is available to them in the coming months, ...
Posted by Michael Wonder on 17 Sep 2022
Swiss regulator gives green light to first drug to prevent Covid-19
16 September 2022 - Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis ...
Posted by Michael Wonder on 17 Sep 2022
CHMP adopts positive opinion to extend indication of Veklury (remdesivir) for the treatment of paediatric patients with COVID-19
16 September 2022 - If granted by the European Commission, Veklury will become the first and only authorised anti-viral treatment for ...
Posted by Michael Wonder on 14 Sep 2022
ATAGI update following COVID-19 meeting (7 September 2022)
14 September 2022 - An update from the Australian Technical Advisory Group on Immunisation following their meeting on 7 September 2022. ...
Posted by Michael Wonder on 13 Sep 2022
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorisation in the European Union for use as a booster for adults aged 18 and older
12 September 2022 - Nuvaxovid is now authorised in the EU for use in adults aged 18 and older as ...